Table 2.
Dup15q syndrome participants
| Participant | Age (months) | Gender | Duplicationa | Epilepsy (active) | Antiepileptic medicationb | ADOS calibrated severity score | ADOS module | Developmental quotient | Cognitive assessment |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 22 | F | Idic | No | N/A | N/A | T | 42.05 | MSEL |
| 2 | 36 | F | Idic | Yes | Lev, Zns, Cbz | N/A | AOSI | 4.86 | MSEL |
| 3 | 37 | M | Idic | No | N/A | 5 | 1 | 67.57 | MSEL |
| 4 | 38 | M | Idic | No | N/A | 8 | 1 | 21.71 | MSEL |
| 5 | 54 | F | Idic | No | N/A | 8 | 1 | 40.74 | MSEL |
| 6 | 56 | M | Idic | No | N/A | 7 | 1 | 46.88 | MSEL |
| 7 | 94 | F | Idic | No | N/A | 9 | 2 | 45 (IQ) | SB-5 |
| 8 | 122 | M | Idic | Yes | Cbz, Ruf | 6 | 1 | 8.87 | MSEL |
| 9 | 144 | F | Idic | Yes | Ltg | 6 | 1 | 52 (NVIQ) | Leiter-R |
| 10 | 144 | F | Idic | Yes | Lev | 6 | 1 | 9.2 | MSEL |
| 11 | 48 | F | Int | No | N/A | 5 | 2 | 102.6 | MSEL |
| 12 | 50 | M | Int | No | N/A | 6 | 1 | 23.5 | MSEL |
| 13 | 54 | M | Int | No | N/A | 10 | 1 | 16.2 | MSEL |
Idic isodicentric, Int interstitial, Lev leviteracitam, Cbz clobazam, Zns zonisamide, Ruf rufinamide, Ltg lamotrigine, N/A not applicable
aDuplication
bMedications